TY  - JOUR
AU  - Milde, Till
AU  - Fangusaro, Jason
AU  - Fisher, Michael J
AU  - Hawkins, Cynthia
AU  - Rodriguez, Fausto J
AU  - Tabori, Uri
AU  - Witt, Olaf
AU  - Zhu, Yuan
AU  - Gutmann, David H
TI  - Optimizing preclinical pediatric low-grade glioma models for meaningful clinical translation.
JO  - Neuro-Oncology
VL  - 25
IS  - 11
SN  - 1522-8517
CY  - Oxford
PB  - Oxford Univ. Press
M1  - DKFZ-2023-01922
SP  - 1920-1931
PY  - 2023
N1  - #EA:B310# / 2023 Nov 2;25(11):1920-1931
AB  - Pediatric low-grade gliomas (pLGGs) are the most common brain tumor in young children. While they are typically associated with good overall survival, children with these central nervous system tumors often experience chronic tumor- and therapy-related morbidities. Moreover, individuals with unresectable tumors frequently have multiple recurrences and persistent neurological symptoms. Deep molecular analyses of pLGGs reveal that they are caused by genetic alterations that converge on a single mitogenic pathway (MEK/ERK), but their growth is heavily influenced by nonneoplastic cells (neurons, T cells, microglia) in their local microenvironment. The interplay between neoplastic cell MEK/ERK pathway activation and stromal cell support necessitates the use of predictive preclinical models to identify the most promising drug candidates for clinical evaluation. As part of a series of white papers focused on pLGGs, we discuss the current status of preclinical pLGG modeling, with the goal of improving clinical translation for children with these common brain tumors.
KW  - MAPK (Other)
KW  - genetically engineered mice (Other)
KW  - pediatric low-grade glioma (Other)
KW  - preclinical models (Other)
KW  - translation (Other)
LB  - PUB:(DE-HGF)16
C6  - pmid:37738646
DO  - DOI:10.1093/neuonc/noad125
UR  - https://inrepo02.dkfz.de/record/283135
ER  -